Bugs, drugs, and HIV: the role of the vaginal microbiome in HIV risk and antiretroviral efficacy for HIV prevention

Lenine J P Liebenberg; Derseree Archary; Aida Sivro; Douglas S Kwon

doi:10.1186/s13073-017-0469-2

Bugs, drugs, and HIV: the role of the vaginal microbiome in HIV risk and antiretroviral efficacy for HIV prevention

Genome Med. 2017 Aug 17;9(1):74. doi: 10.1186/s13073-017-0469-2.

Authors

Lenine J P Liebenberg^{1

2}, Derseree Archary^{3

4}, Aida Sivro³, Douglas S Kwon^{5

6}

Affiliations

¹ Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa. [email protected].
² Department of Medical Microbiology, University of KwaZulu-Natal, Durban, South Africa. [email protected].
³ Centre for the AIDS Programme of Research in South Africa (CAPRISA), University of KwaZulu-Natal, Durban, South Africa.
⁴ Department of Medical Microbiology, University of KwaZulu-Natal, Durban, South Africa.
⁵ Ragon Institute of MGH, MIT, and Harvard, Harvard Medical School, Cambridge, MA, USA. [email protected].
⁶ Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA. [email protected].

Abstract

Advances in molecular tools to characterize the microbiome have led to the discovery of unique roles for microbes in human disease. Findings that the female genital microbiome can influence HIV acquisition and prevention emphasize the importance of microbiome analysis in clinical trials that assess the efficacy of HIV prevention interventions.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review

MeSH terms

Anti-Bacterial Agents / therapeutic use
Anti-HIV Agents / therapeutic use*
Female
HIV Infections / drug therapy
HIV Infections / epidemiology
HIV Infections / microbiology*
HIV Infections / prevention & control
Humans
Microbiota*
Vagina / microbiology*

Substances

Anti-Bacterial Agents
Anti-HIV Agents